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Abstract
Background: Endometrial cancer represents a tumor entity with a great variation in its incidence
throughout the world (range 1 to 25). This suggests enormous possibilities of cancer prevention
due to the fact that the incidence is very much endocrine-related, chiefly with obesity, and thus
most frequent in the developed world. As far as treatment is concerned, it is generally accepted
that surgery represents the first choice of treatment. However, several recommendations seem
reasonable especially with lymphadenectomy, even though they are not based on evidence. All high-
risk cases are generally recommended for radiotherapy.
Methods: A literature search of the Medline was carried out for all articles on endometrial
carcinoma related to diagnosis and treatment. The articles were systematically reviewed and were
categorized into incidence, etiology, precancerosis, early diagnosis, classification, staging,
prevention, and treatment. The article is organized into several similar subheadings.
Conclusions: In spite of the overall good prognosis during the early stages of the disease, the
survival is poor in advanced stages or recurrences. Diagnostic measures are very well able to detect
asymptomatic recurrences. These only seem justified if patients' chances are likely to improve,
otherwise such measures increases costs as well as decrease the patients' quality of life. To date
neither current nor improved concepts of endocrine treatment or chemotherapy have been able
to substantially increase patients' chances of survival. Therefore, newer concepts into the use of
antibodies e.g. trastuzumab in HER2-overexpressing tumors and the newer endocrine compounds
will need to be investigated. Furthermore, it would seem highly desirable if future studies were to
identify valid criteria for an individualized management, thereby maximizing the benefits and
minimizing the risks.
Incidence and mortality
Nearly 170,000 new cases of endometrial carcinomas
were estimated worldwide in 1997 [1]. However, inci-
dences throughout different regions of the world vary
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considerably. Compared to Africa and Asia having the
lowest rates of incidence, Western Europe, USA and Can-
ada are shown to have the highest incidence worldwide
(Figure 1). As shown in figure 2, even within Europe the
incidence rates are very heterogeneous. In some of these
countries, e.g. Germany, endometrial carcinoma is the
most common among genital carcinoma [2].
Endometrial carcinomas occur in advanced age (postmen-
opausal). The age-related incidence for Germany is shown
in Figure 3. The overall increase in the incidence of this
disease during the last decades is mainly related to higher
life expectancy within the developed world.
Etiology and risk factors
The etiology of the endometrial carcinoma is not fully
understood. Most cases appear sporadically whereas
about 10% are hereditary. Chief among the latter is the
autosomal dominantly inherited hereditary non-polypo-
sis colorectal cancer (HNPCC) [3-5]. The risk of develop-
ing endometrial cancer is believed to be ten times higher
for women carrying the gene compared to the general
population [6]. The likelihood of a synchronous or meta-
chronous development of endometrial carcinomas is,
however, higher for patients with breast, ovarian, and
non-hereditary colorectal cancer [7].
Within the current concept of multi-step progression of
normal cells to malignancy, recent molecular work has
identified several gene alterations important for tumor
development. In summary, mutations and amplifications
of oncogenes K-ras and HER2/neu, mutations or deletions
of tumor suppressor genes p53, p21, p16, and pTEN/
MMAC1 as well as impaired DNA repair functions
Estimated endometrial cancer incidences throughout different regions of the world [1] Figure 1
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through mutations of hMLH1, hMSH2, and hMSH6 have
been connected with the development of endometrial car-
cinomas [8].
Environmental, dietary and hormonal factors as well as an
aging female population have been attributed to an
observed increase of endometrial carcinomas over the
past few years. Epidemiologic studies have observed cor-
relations between the incidence of endometrial cancer
and the usage of estrogens, especially when applied to
alleviate perimenopausal and postmenopausal symp-
toms. Therefore, it appears that estrogen plays a key role
in the development and progression of endometrial
carcinomas.
There is also convincing evidence that high body mass
increases the risk of endometrial carcinomas. Current esti-
mations figure that about 40% of these relate to excess
body weight [9]. A plausible biological explanation for
obesity influencing the risk of endometrial cancer is found
in increased aromatization of androstendione to estrone
in adipose tissue [10]. Hyperadrenocorticism, which is
more common in obese individuals, also disturbs the
estrogen metabolism. The correlation between obesity
and hyperadrenocorticism is possibly increased by hyper-
insulinism. This also explains the higher frequency of
endometrial carcinomas in combination with diabetes
mellitus. A high intake of saturated fat may also increase
the risk, whereas high consumption of vegetables and
Estimated endometrial cancer incidences throughout different countries in Europe [1] Figure 2
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fruits may do the opposite [1,11]. Due to the fact that
most factors relate to prolonged or intensive exposure to
estrogen (hyperestrogenism), this may likely be identified
as the underlying concept leading to the development of
endometrial cancer. In this process estrogens are believed
not to act as carcinogenic agents, but as promoters of car-
cinogenesis. A state of hyperestrogenism may be caused
by exogenous or endogenous factors and may relate to
reproductive factors, estrogen exposure or menopausal
years [9,12,13]. Several endogenous risk factors are also
associated with the increase of endometrial cancer risk e.g.
early menarche, late menopause (2.4-fold), nulliparity (2-
fold), the polycystic ovarian syndrome, diabetes mellitus
(2.8-fold), high blood pressure (1.5-fold), obesity (up to
10-fold), other tumors with estrogen production, atypical
endometrial hyperplasia (see Table 1) and the aforemen-
tioned inherited forms of colorectal cancer (10-fold).
Basically two hypotheses endeavor to explain the protec-
Age dependent incidence of endometrial cancer in Germany Figure 3
Age dependent incidence of endometrial cancer in Germany. Robert-Koch-Institute at: http://www.rki.de/GBE/KREBS/
BROSCHUERE2002/BROSCHUERE2002.HTM
Table 1: Type of endometrial hyperplasia and rate of progression 
to cancer [20].
Type of hyperplasia Rate of progression
Simple (cystic without atypia) 1
Complex (adenomatous without atypia) 3
Atypical
Simple (cystic with atypia) 8
Complex (adenomatous with atypia) 29World Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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tive effect of high parity: The first one assuming the
mechanical removal of premalignant and malignant cells
with each delivery, the second describing a protective
effect of high progesterone values during pregnancy. It is
most likely for both hypotheses to be correct to some
extent, whereas a large population based study from Fin-
land favors the second hypothesis [14]. An additional fac-
tor may be anovulatory ovarian insufficiency, especially in
patients with polycystic ovaries (PCO syndrome). As these
patients have a persistent progesterone deficiency due to
non-formation of a corpus luteum, they lack this impor-
tant protective mechanism. Endocrine risk factors also
include hormone producing ovarian tumors. This goes for
estrogen as well as androgen producing tumors since
androgens may be converted to estrone in adipose tissue.
Previous irradiation of the pelvis, estrogen replacement
therapy (HRT) (especially unopposed HRT) and
tamoxifen therapy represent exogenous risk factors. Pro-
longed and exclusive intake of synthetic estrogens is asso-
ciated with an up to 15-fold higher incidence of
endometrial carcinomas [15]. Similarly, some selective
estrogen receptor modulators (SERMs) and especially
tamoxifen may have an estrogenic, proliferative effect on
the endometrium. Thus tamoxifen therapy is frequently
associated with polyps, hyperplasia and carcinomas of the
endometrium [16,17]. Tamoxifen seems to induce a 6.4-
fold increase in the risk for endometrial cancer [18]. On
the other hand, cyclic application of estrogens combined
with progestins does not increase endometrial cancer inci-
dence, e.g. hormonal contraception (combined prepara-
tions) and may even reduces the risk of endometrial
carcinomas by up to 50% (see prevention). In essence,
hyperestrogenism will lead to stronger proliferation,
thereby causing hyperplasia which may gradually acquire
more and more cellular atypia (atypical hyperplasia) and
later transform into an endometrioid adenocarcinoma.
Recently a case-control study identified antipsychotic
drugs as being a great risk factor for endometrial cancer
[19]. These findings may also be explained to some extent
by the side effects of the drugs (obesity, insulin resistance,
amenorrhea, low gonadal steroids leading to
hyperprolactinemia).
Precancerosis
In some cases endometrial cancer develops from atypical
endometrial hyperplasia. The likelihood of this happen-
ing correlates with the degree of hyperplasia (Table 1)
[20]. According to the World Health Organization
(WHO) classification, endometrioid carcinomas are
divided into simple and complex forms, each with and
without atypia [21]. This classification has also been
accepted by the International Society of Gynecological
Pathologists.
Endometrial hyperplasia is regarded as a preliminary stage
of endometrioid carcinomas. Serous and clear cell carci-
nomas are on the other hand frequently associated with
an atrophic endometrium [22]. A precursor of the serous
carcinoma and possibly of some clear cell carcinomas is
the endometrial intraepithelial carcinoma (EIC) [22,23].
Prevention
To prevent an outbreak of the disease in menopausal and
postmenopausal women long-term estrogen replacement
therapy (treatment of menopausal symptoms, osteoporo-
sis etc.) should be supplemented by intermittent applica-
tion of gestagens. A recent study suggested the use of
intrauterine devices (IUD) also possibly reducing the risk
for endometrial cancer due to improved elimination or
decrease of hyperplastic endometrial cells [24]. Numerous
studies have shown that cigarette smoke reduces the risk
of an endometrial carcinoma for women after the meno-
pause, although it may increase the risk for premenopau-
sal women [25]. The greatest reduction of risk was found
in obese, multiparous women who did not receive hor-
mone treatment [26]. Women in advanced stages of dis-
ease (stages II – IV), however, were found more likely to
smoke than women in early stages (0 – I). This may reflect
a smoking-related decrease in the incidence of early-stage
tumors as well as an increase in tumor invasiveness and
metastases [27]. The risk of endometrial carcinomas may
be reduced significantly by prolonged progestin therapy
every month (for 10 days) alone or in combination with
estrogen [28]. Since progestins are known to act as cofac-
tors of cancerization in breast and cervical cancer such
concepts are better interpreted cautiously [29]. Therefore
hormonal preventive concepts need to undergo a general
assessment of benefits and risks. To sum up, apart from
excess body fat reduction and omission of unnecessary
estrogen therapy, there appears to be no reasonable way of
preventing endometrial carcinomas.
Early detection
To date there is no procedure that seems appropriate as a
screening method for early detection of endometrial
carcinomas. Current guidelines of the American Cancer
Society suggest informing patients of risks and symptoms
involved with endometrial cancer and furthermore firmly
emphasize the importance of reporting unexpected bleed-
ing or spots to their physician [30]. The fact of most
endometrial carcinomas (with the exception of the rare
serous and clear cell types) showing these kinds of prelim-
inary symptoms leads to the diagnosis of over 75% of
cases while still in stage I [7]. A recent case-report on the
usage of the Mirena® intrauterine system maintains that
irregular menstrual bleeding should not be treated simply
with this system without prior diagnostic [31].World Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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The necessity of finding a screening method is discussed
controversially in this context. So far, most epidemiologi-
cal studies have failed to show significant effects of screen-
ing on mortality.
In some cases the Pap smear may lead to the diagnosis of
endometrial cancer. However, in many cases cells from
inside the uterus are not assessed by the sampling proce-
dure. Positive cervical cytology was found to correlate
with nodal spread in 91% of cases, whereas the risk of
lymph node spread in patients with normal cervical cytol-
ogy was estimated at around 2% [32]. It would seem too
early to suggest that this could help to reach a decision on
the necessity of lymphadenectomy. Maybe the ThinPrep
Pap tests will be able to allow further conclusions in the
future [33].
Transvaginal ultrasound has also been suggested as a
potential means of early detection of endometrial carcino-
mas. A recent meta-analysis involving 9,031 patients and
covering 57 separate studies on the diagnostic accuracy
and positive predictive power of endometrial thickness
measurement by pelvic ultrasound in patients with post-
menopausal bleeding concluded that these measurements
cannot solely be used to accurately rule out endometrial
pathology. Measurement of both endometrial layers of ≤
5 mm coincides with endometrial pathology in only 2.5%
[34]. Other studies have used saline infusion sonography
and color Doppler sonography to differentiate between
endometrial cancer, endometrial hyperplasia, fibroids,
endometriosis, myoma or tamoxifen induced endome-
trial thickness [35-42]. A recent comparison of saline infu-
sion sonography and office hysteroscopy revealed similar
ratings of patients' pelvic pain during the procedures. Sen-
sitivity and specificity coefficients as well as negative and
positive predictive values were higher for the office hyster-
oscopy [43].
It seems that biopsy remains the only accurate way of
diagnosing endometrial cancer [44]. Under optimal cir-
cumstances the gynecologist will remove a tissue sample
from the uterine lining under hysteroscopic control [44-
47]. If hysteroscopic control is neglected, the false nega-
tive rates for dilatation and curettage (D&C) will range
between two and six percent, thereby emphasizing the
limitations of D&C alone [45,48-50].
Newer methods, like magnetic resonance imaging (MRI),
positron emission tomography (PET), intraoperative
ultrasound or three dimensional sonography are not
likely to gain importance with respect to the diagnosis or
early diagnosis of the disease [51-56]. It is, however, rea-
sonable to believe that they are likely to deliver more
information about the invasion depth of the myometrium
or lymphatic metastases [52,55,57].
Classification of endometrial carcinoma
The term endometrial carcinoma describes a variety of dif-
ferent tumor types originating from the inner ling of the
uterus. Many authors differentiate between two basic
types, which may be divided into estrogen-dependent and
estrogen-independent types or tumors with favorable or
unfavorable prognosis [58]. Although there are no cross-
sectional studies comparing tumors from various ethnic
groups and significant differences in tumor biology the
frequency of tumors of a certain category in various geo-
graphical areas have been assumed. This may explain why
mortality in the USA is higher in black women than in
white women (5.8 deaths per 100,000 persons in black
women vs. 3.1 deaths per 100,000 persons in white
women) [59]. The different categories may be summa-
rized as follows:
1. It comprises of estrogen related tumors occurring in
younger, perimenopausal women. These tumors are often
said to be highly differentiated, mainly adenocarcinomas
with positive steroid hormone receptor status (ER, PR),
the known risk factors (estrogen etc.) originating from
atypical endometrial hyperplasia. The patients in this
group have a longer history, lower grade tumors, less myo-
metrial invasion and low potential for lymphatic spread.
They may be associated with concomitant carcinomas of
the ovary, breast and colon and respond to progestin ther-
apy. The overall prognosis is generally favorable.
2. This category is comprised of tumors of patients with
shorter history, higher grade tumors, deeper myometrial
invasion and high risk of lymphatic spread. The tumors
will not respond to progestin therapy and there are no
associated tumors. Histologically these tumors are identi-
fied as serous carcinomas or clear cell adenocarcinomas.
The prognosis of patients with this type of tumor is poor.
3. Findings of carcinomas in atrophic endometrium being
associated with an intermediate prognosis lead to the sug-
gestion of a third category. In these cases the endometri-
oid carcinomas are not likely to be estrogen-related [21].
4. It was furthermore suggested to incorporate endome-
trial neoplasia originating from an inherited predisposi-
tion into a fourth category. These types of tumors tend to
develop about 15 years earlier and are associated with a
favorable prognosis. Most patients in this category have a
hereditary non-polyposis colorectal carcinoma syndrome
(HNPCC).
Histological types according to the WHO 
classification
The following section will briefly describe the most
important characteristics of endometrial carcinomas.World Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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Detailed descriptions may be found in specialized patho-
logical textbooks e.g. Anderson et al. [21].
• Endometrioid adenocarcinoma: The endometrioid adeno-
carcinoma, whose glands resemble those of the normal
endometrium, is the most common type (60 – 80%). This
type is considered part of the 1st category
• Endometrioid adenocarcinoma with squamous cell differenti-
ation  (adenoacanthoma, adenosquamous carcinoma):
Approximately 25% of endometrioid adenocarcinomas
display partial squamous differentiation. The squamous
elements are interpreted as terminally differentiated indicat-
ing that the tumor is incapable of independent growth.
Prognosis depends on the glandular components of the
lesion. Highly differentiated tumors (adenoacanthomata)
have a favorable prognosis, whereas poorly differentiated
tumors (adenosquamous carcinomas) have an unfavora-
ble course.
• Serous adenocarcinoma: This tumor type is similar to the
serous ovarian carcinoma. It is characterized by aggressive
growth and poor prognosis. Lymphogenic and hema-
togenic metastases are usually already present at the time
of diagnosis. Nearly all tumors are poorly differentiated.
Serous adenocarcinomas belong to the 2nd category of
endometrial cancer.
• Clear cell adenocarcinoma: This type comprises 3 to 6% of
all endometrial carcinomas. Like the serous adenocarci-
noma, clear cell adenocarcinomas tend to progress rap-
idly. They share the 2nd category.
•  Mucinous adenocarcinoma: Diagnosis is based on the
presence of mucus within the tumor cells. Purely
mucinous carcinomas are rare, although a mucinous com-
ponent within endometrioid carcinomas is more com-
mon. The tumors are usually highly differentiated and
have a good prognosis. It is important to exclude a pri-
mary mucinous adenocarcinoma originating from the
endocervix, spreading into the uterine body. Mucinous
adenocarcinomas are part of the 1st category.
• Squamous cell carcinoma (2nd category): A very rare entity
associated with very poor survival. Primary squamous cell
carcinomas of the uterine cervix should be ruled out.
Adjuvant platinum-based radiochemotherapy may result
in improved survival.
• Mixed carcinoma: A carcinoma composed of two or more
different non-squamocellular components with each
component occupying at least 10% of the tumor. Progno-
sis varies, e.g. in case of a serous component, the progno-
sis is poor.
•  Undifferentiated carcinoma: A rare carcinoma without
glandular, squamous or sarcomatous differentiation.
Prognosis is unfavorable.
• Rare types of endometrial carcinomas: small cell carci-
nomas, microglandular adenocarcinomas, signet-ring cell
carcinomas, transitional cell carcinomas, glassy cell carci-
nomas, mucinous adenocarcinomas of the intestinal type,
lymphoepithelioma-like carcinomas, and endometrial
adenocarcinomas with trophoblastic differentiation have
been reported.
Grading
The tumor grading is a highly significant prognostic
parameter although it is subjective with a considerable
inter-observer and intra-observer variability. It is deter-
mined by the percentage of non-squamocellular, solid
portions as follows: G1: 5% and less, G2: 5–50%, G3:
more than 50%. A significant nuclear atypia increases the
grade of differentiation by one grade.
Preoperative diagnostic procedures
After histological confirmation of an endometrial carci-
noma clinical palpation and vaginal sonography should
be performed. Several additional examinations have been
suggested: Rectoscopy, cystoscopy, computed tomogra-
phy and/or MRI. They may be omitted in clearly diag-
nosed early cases but are strongly recommended in
advanced stages. Recent studies indicate some value of
tumor marker diagnostics. At a cut-off level of 40 U/ml
elevated CA125 serum levels indicate nodal metastases
with a sensitivity of 77.8% and a specificity of 81.1%
[60,61].
Surgical therapy
In all stages of endometrial carcinomas, surgery is the pri-
mary treatment of choice. Preoperative intracavitary radi-
ation treatment, often recommended in earlier times, is
not considered advisable any more since the information
about the depth of myometrial invasion and thus infor-
mation on an important prognostic factors is lost [62]. A
study indicates that the Maylard-type incision is superior
to transverse (Pfannenstiel-type) or longitudinal incision
[63]. If possible, an abdominal hysterectomy with
removal of the adnexa and a peritoneal lavage should be
performed. After removal of the uterus, the depth of
tumor invasion into the myometrium has to be deter-
mined to estimate the probability of extrauterine spread.
If the myometrium is infiltrated to more than 50%, a pel-
vic and paraaortic lymphadenectomy should be per-
formed. For appropriate staging, more than 20 lymph
nodes should be dissected [64]. But also in cases of addi-
tional adverse prognostic factors (poor grading, lym-
phangiosis, see below), pelvic and paraaortic
lymphadenectomy are recommended by many [65]. AWorld Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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decision tree on primary therapy is given in figure 4.
Unfortunately, studies found no correlation between
depth of invasion, histological grade, cervical invasion,
peritoneal cytology, menopausal status, preoperative
serum CA125 level or primary tumor diameter. Only lym-
phvascular space involvement (P < 0.0001) was signifi-
cantly correlated to pelvic lymph node metastases, which
lead the authors to the conclusion that all patients should
undergo extended surgical staging, except when clinical or
operative factors increase patients' morbidity [66]. Lym-
phadenectomy may be omitted in cases of more favorable
prognosis.
There is some controversy on the value of radical hysterec-
tomy in stage II carcinomas. While several earlier studies
advocated this procedure [67-70] a recent study reported
no prognostic advantage [71]. Maybe only the patients
with stage IIb tumors and clinically evident tumor infiltra-
tion profit from radical hysterectomy. This requires fur-
ther investigation.
Complications after pelvic lymphadenectomy may be
reduced by omentoplasty and omentopexy [72]. In
advanced stages of the disease complete removal of all
tumor sites is warranted. In case of serous histology and
peritoneal spread, some authors also advocate omentec-
tomy. A recent study indicates that optimal cytoreduction
results in a significant survival benefit for stage IVB
endometrial cancer patients with a reasonable surgical
morbidity rate [73].
Vaginal hysterectomy as primary treatment of endome-
trial cancer has also been investigated especially in medi-
cally compromised women [72,73]. Such approaches may
be combined successfully with laparoscopically assisted
radical vaginal hysterectomy [74-77].
The aforementioned basic goals of surgery (hysterectomy,
removal of the adnexa and lymphadenectomy in stages Ic
and higher) should be reached especially in medically fit
patients, because treatment along the recognized guide-
lines has been found to be prognostically favorable. Some
studies, however, have reported the standards mentioned
in many cases as not having been realized [78-80]. As
shown in Italy there seems to be certain reluctance
towards bringing current topics discussed in literature into
practice [81].
The problem mentioned may partly be due to the fact that
the current guidelines are insufficiently supported by ran-
domized surgical trials. Interestingly the COSA-NZ-UK
Endometrial Cancer Study Group trial showed that lym-
phadenectomy showed no advantage for endometrial
cancer if primary surgery was followed by adjuvant radio-
therapy [82]. Therefore studies on all surgical aspects are
warranted. This also includes newer surgical approaches
which await further evaluation in prospective studies.
Staging
Endometrial carcinomas are staged surgically. Procedures
previously used for determination of stages, such as frac-
tional dilatation and curettage to differentiate between
stage I and II, are no longer applicable unless the patient
Decision tree concerning the primary treatment of endometrial carcinoma Figure 4
Decision tree concerning the primary treatment of endometrial carcinoma.Legend: RT = radiotherapy; HT = endocrine treat-
ment; CHT = chemotherapy; D&C = dilatation and curettageWorld Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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is to be treated by primary radiation therapy. The old
(1971) and new (1988) staging system of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
are shown in table 2. The prognostic importance of ade-
quate surgical staging was recently demonstrated [83].
Prognostic and predictive factors
Tumor stage, patient age, histologic type and grade, hor-
mone receptors and DNA ploidy represent the traditional
prognostic factors. Respective of the response to progestin
therapy steroid hormone receptors may also be regarded a
predictive factors in recurrent and advanced disease [8].
The strong prognostic impact of tumor stage is underlined
by the cumulative 5-year survival rates (surgical/patholog-
ical staging) which are 85% for stage I, 70% for stage II,
49% for stage III and 18% for stage IV disease. Obviously
both major factors which make up the staging system of
endometrial carcinomas, depth of invasion into the myo-
metrium and lymph node status, are major prognostic fac-
tors [84,85]. A recently published analysis draws the
attention to lymphvascular space involvement and sug-
gests that its presence should indicate lymphadenectomy
or adjuvant therapy [86]. Lymphvascular space involve-
ment was also closely linked with advanced stage (unpub-
lished observation). Furthermore, several additional
prognostic factors have been suggested: Nulliparity, high
tumor cell proliferation (KI-67), high tumor vessel density
(angiogenesis), oncogene amplification or overexpression
(HER2/neu, K-ras) and alterations of tumor suppressor
genes (PTEN, p53, p21, p16) are believed to be associated
with adverse prognoses. Especially Ki-67 could be of
greater importance seeing that this parameter proved to be
independent in multifactorial analyses in a prospective
study [87].
There is a divergence of opinion concerning the value of a
positive peritoneal cytology as an independent prognostic
factor [88]. In stage I, depth of myometrial invasion, vas-
cular invasion, mitosis count and progesterone receptor
negativity are statistically significant prognostic factors
[89,90]. Overexpression of p53 is observed in approxi-
mately 20% of all endometrial carcinomas and in up to
90% of serous carcinomas [91]. The plasminogen activa-
tor inhibitor type 2 has been discussed as a possible inde-
pendent prognostic marker [92]. Overexpression of the
oncogene Her-2/neu is significantly more common in
advanced than in early stages. Finally, ploidy status is
possibly an independent prognostic factor [93], with ane-
uploidy being mainly associated to prognostically unfavo-
rable serous, clear cell and poorly differentiated
carcinomas. There are, unfortunately, still too many con-
troversies to draw final conclusions or even to make sug-
gestions on factors to be determined routinely.
Radiotherapy
Primary radiotherapy
In medically compromised women, primary irradiation
may be suitable. Analyses from Germany show that
approximately 20% of all patients undergo primary radi-
otherapy [7,64]. There are three possible approaches: The
after loading technique alone, a combination of after
loading and percutaneous techniques or by percutaneous
radiotherapy alone. The literature also reports on consid-
erable variation in the number of fractions and the doses
of each fraction [64]. In case of brachytherapy only 5 × 8
Gy or 8 × 5 Gy may be applied. Combined therapy usually
delivers 50 Gy percutaneously with partial blocking of the
bladder and intestines after 24 and 30 Gy and 2 to 5 frac-
tions via brachytherapy. Brachytherapy may also be
applied before commencement of percutaneous therapy.
The selected dose may be applied by a variety of
Table 2: Tumor classification of the international Federation of Obstetrics and Gynecology (FIGO). The surgical staging system is 
obligatory unless patients are to undergo primary radiotherapy when the older clinical staging system may be used.
Stage Stage – Clinical Staging Stage – Surgical Staging
I I Carcinoma confined to corpus Ia Tumor limited to endometrium
Ia Length of uterine cavity ≤ 8 cm Ib Invasion ≤ 1/2 myometrium
Ib Length of uterine cavity > 8 cm Ic Invasion > 1/2 myometrium
II II Carcinoma involves corpus and cervix IIa Endocervical glandular involvement only
IIb Cervical stromal invasion
III III Carcinoma extends outside uterus but not 
outside the true pelvis
IIIa Tumor invades serosa or adnexa or positive peritoneal cytology
IIIb Vaginal metastasis
IIIc Metastases to pelvic or para-aortic lymph nodes
VI IV Carcinoma extents outside true pelvis or 
involves bladder or rectum
IVa Tumor invades bladder, bowel mucosa, or both
IVb Distant metastases, including intra-abdominal and/or inguinal lymph 
nodesWorld Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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techniques e.g. by Heyman capsules, double-rod-shaped
applicators, indwelling applicators etc. [64]. An appropri-
ate applicator should ensure adequate irradiation of the
entire uterus [94]. Nowadays, computer controlled treat-
ment planning allows optimal treatment planning and an
individual adaptation of the dose distribution to the uter-
ine cavity. This may vary between patients of course.
Only few clinical trials on primary radiotherapy have been
performed. The results suggest that dividing doses into
smaller fractions allows better tumor control and has less
side effects [95]. The old question on high-dose-rate or
low-dose-rate after loading still remains unsolved. There
is still limited data on the efficiency of primary radiother-
apy in endometrial carcinomas. An analysis of 154
patients having undergone primary radiotherapy at our
department showed that local recurrences are more com-
mon in this group compared to surgery and adjuvant radi-
otherapy. The rates of recurrences are stage dependent:
23.3% vs. 13.2% in stage I and 39.2% vs. 25.9% in stage
II [7]. As shown in figure 5 there is a significant difference
in overall survival between both groups. Thus, primary
radiotherapy represents an effective but suboptimal meas-
ure for this group of patients being in generally poorer
physical condition.
Adjuvant postoperative irradiation
Most studies indicate that advance age, grade 3 histology
or deep myometrial invasion relate to a higher risk of dis-
ease recurrence. Therefore adjuvant radiotherapy seems
important in this subset. External beam radiation should
also be considered in cases of multiple infiltrated lymph
nodes (> 5). But many questions remain unanswered and
the value of postoperative irradiation is still under debate.
Survival rates of patients with early stage disease are excel-
lent, no matter whether they underwent extended-surgical
staging with more restricted use of the adjuvant therapy or
simple hysterectomy bilateral salpingoophorectomy with
more frequent use of adjuvant radiotherapy [96]. Prospec-
tive-randomized trials have so far only demonstrated
improved local control yet no overall survival benefit, and
have higher rates of treatment related complications [97].
This accords to larger retrospective analyses, most likely
due to the fact that the majority of these recurrences can
be salvaged through radiation therapy [98]. With respect
to the importance of the problem, trials to evaluate the
therapeutic benefit of adjuvant radiotherapy in the several
subsets of patients at higher risk are warranted.
The American Brachytherapy Society has now issued rec-
ommendations for brachytherapy for carcinomas of the
endometrium [94]. According to these, the applicator
selection should be based on patient and target volume
geometry, the dose prescription point should be clearly
specified and the treatment plan should be optimized. For
intravaginal brachytherapy selection of the largest diame-
ter applicator is to ensure close mucosal apposition.
Finally, doses should be reported both at the vaginal
Decision tree concerning the treatment of recurrent endometrial carcinoma     Figure 5
Decision tree concerning the treatment of recurrent endometrial carcinoma.Legend: ENCA = endometrial carcinoma; QoL = 
Quality of Life; RT = radiotherapy; HT = endocrine treatment; CHT = chemotherapy;World Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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surface and at 0.5-cm depth irrespective of the dose pre-
scription point.
Adjuvant medical treatment
The data on adjuvant medical treatment is not conclusive.
Most studies have their limitations and therefore there is
still no final answer to the question, who should receive
what type of adjuvant treatment. Merely in cases of uterine
papillary serous carcinomas, which affect 1% to 10% of
patients, there is consensus that patients should receive
chemotherapy (with or without adjuvant radiotherapy)
with a platinum-based regimen, combined with doxoru-
bicin and cyclophosphamide. Newer regimens consider
paclitaxel, with or without platinum [99].
Adjuvant hormonal treatment
A multicenter, open, controlled, prospectively rand-
omized trial on adjuvant endocrine treatment with
medroxyprogesterone acetate (MPA) or tamoxifen in stage
I and II endometrial carcinomas failed to detect differ-
ences in the disease-free and overall survival rates for a
tamoxifen group compared with a control or a MPA group
[100]. However, the total number of patients on trial (n =
388) seems too low in relation to the favorable prognosis
of early stage disease and the low total response rate of
tamoxifen which ranged around 10% in this situation
[101]. In the aforementioned study tamoxifen demon-
strated only modest activity which lead the authors to the
conclusion that tamoxifen does not warrant further inves-
tigation as a single agent but perhaps a sequential use of
tamoxifen and progestational agents [101].
Adjuvant chemotherapy
The generally good prognosis of endometrial carcinomas
does not justify a general recommendation of chemother-
apy, especially in the early stages. Even so, patients at high
risk (unfavorable histological type, deep myometrial inva-
sion and lymph-vascular space involvement) seem to
profit from adjuvant chemotherapy [102,103]. Studies on
the subject unfortunately often lack a control arm so the
effects of chemotherapy remain unclear [104]. Well
designed studies in the group of high risk patients are
warranted.
Preservation of fertility
The development of endometrial cancer in young patients
is usually related to unopposed estrogen stimulation. In
patients with continuing a desire to have children,
approaches have been made to preserve fertility. Primary
hormonal therapy with progestins was suggested as an
alternative treatment for surgery hereby offering the pres-
ervation of fertility. These must be interpreted with cau-
tion because of low case numbers and a publication bias.
Treatment with megestrol acetate at 160 mg/day for 3
months or medroxyprogesterone acetate (MPA) at 200–
800 mg/day for 2–14 months resulted in disease regres-
sion in 60 to 75%, however, the percentage of patients
who actually delivered healthy children was much lower,
ranging from 20 to 25% [105-107]. Furthermore, in sev-
eral patients, persistent or recurrent disease was observed
at the time of a later hysterectomy. In all these cases of
unsatisfactory progestin therapy and delayed definitive
surgical treatment may have adversely affected patient
prognosis.
In essence, the problems regarding the optimal selection
of patients for conservative progestin therapy are
unsolved. Only cases with good prognostic factors are to
be selected: Well differentiated tumors and tumors with
known favorable prognoses (e. g. endometrioid type
tumors) with no or minimal myometrial invasion and
early stage disease. The greatest problem lies in the diffi-
culty of appropriate staging, resulting in a potential
underestimation of the problem. Maybe positron emis-
sion tomography, magnetic resonance imaging or a com-
bination of both may be useful in this respect in due
course.
Patients have to be carefully informed that this fertility
preserving concept is still experimental. Moreover, these
women must realize the low overall pregnancy rate which
may partially be related to the origin of the disease (obes-
ity, irregular menses, polycystic ovarian disease (PCOD)
with chronic anovulation and infertility) [108].
Nowadays when treatment of infertility is frequently
offered to elderly women, such conservative treatments
should, however be investigated more thoroughly. Fur-
ther questions concern follow-up of these patients. In the
aforementioned studies, many patients were treated with
maintenance therapy (oral contraceptives or cyclic pro-
gestins) to prevent recurrence, which was excluded by rou-
tine combination of sonography and D&C every 3–6
months.
Palliative treatment – treatment of local 
recurrences
Generally the prognosis for patients with recurrent disease
is poor, therefore a thorough staging procedure should be
performed. Analyses from other tumor entities, e.g.
ovarian carcinomas, have demonstrated that a second sur-
gical intervention may be useful in improving patients'
overall survival [109,110]. Thus, even in absence of clini-
cal studies on the subject, patients with single site recur-
rence should be evaluated for their suitability to surgery at
relapse. In patients with isolated central recurrences, pel-
vic exenteration may be a potential option for cure [111].
The choice with respect to therapy of cancer recurrence
strongly depends on prior treatment. In case of prior radi-
otherapy, a second intervention may often not be possi-
ble. If radiotherapy is possible, only nonbulky vaginalWorld Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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recurrences (< 0.5-cm thick) should be treated by intrac-
avitary brachytherapy. Patients with bulky (> 0.5-cm
thick) recurrences should receive interstitial techniques
[94]. A general decision tree regarding the procedures in
case of a recurrence is depicted in figure 6. Regarding the
decision, whether or not to start with endocrine or cyto-
toxic treatment, the individual risk seems important. But
equally important are aspects of patients' quality of life. A
risk assessment scale, which was originally introduced by
Possinger for breast cancer, seems helpful [108]. Similar
to the adjuvant situation, treatment with tamoxifen,
medroxyprogesterone acetate (MPA) alone or in combi-
nation may be used. However, there are only few, rela-
tively old studies on the topic, all of which do not allow a
final conclusion on the value of such therapies. MPA
seems to be the best substance producing remission rates
up to 80% in receptor positive tumors [113]. Remission
rates of tamoxifen range around 25–30%. After failure of
MPA, tamoxifen may be added to MPA producing remis-
sion rates in this combination of 50–60% [114]. Also
aminogluthemide seems to be active in endometrial can-
cer [115]. Responses to all kinds of treatments unfortu-
nately do not tend to last for long.
Some studies also suggest a potential benefit for luteiniz-
ing hormone-releasing hormone analogues (GnRH),
although studies in endometrial carcinomas have not
shown any convincing activity [116-118]. To sum, up on
the background of the few and old studies with often low
case numbers, newer large studies on endocrine strategies
are warranted.
With respect to chemotherapy, several cyctostatic com-
pounds have demonstrated efficiency. Among these are
paclitaxel, carboplatinum, doxorubicin, cisplatin, etopo-
side, and 5 fluorouracil. Topotecan showed only limited
activity [119-124]. All drugs may be used alone or in com-
bination, perhaps even in combination with hormonal
therapy [125,126]. Again, realizing that combination
chemotherapy produces greater side effects, every option,
endocrine treatment, single drug or combination chemo-
therapy should be considered.
Follow-up
Generally recommendation for clinical follow-up of
patients advocate patients to be monitored at three-
monthly intervals during the first 3 years, at 6-monthly
Comparison of overall survival between patients undergoing surgery and radiotherapy or primary radiotherapy Figure 6
Comparison of overall survival between patients undergoing surgery and radiotherapy or primary radiotherapy. Note that 
patients in the group undergoing primary radiotherapy were generally olderWorld Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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intervals up to the 5th year and at yearly intervals thereaf-
ter. Apart from provision of general information on all
aspects of the disease and its treatment including uncon-
ventional cancer therapies, the documentation of
patients' history, a clinical gynecological examination
including a pap smear, a vaginal sonography and even the
determination of tumor markers (SCC, CA125) have been
recommended. Up to 95% of all recurrences may be
detected early this way [127]. Again there are no prospec-
tive studies on the subject to enforce such recommenda-
tions. On the contrary, several retrospective studies
indicate that an intensive follow-up does not result in a
survival advantage for patients with recurrent disease but
merely increases costs [7,128-131]. Also in this area the
most appropriate management of endometrial carcino-
mas remains to be determined. In any case an annual
examination of the breast, including mammography, is
recommended, due to the fact of the frequent coincidence
of malignancies of the breast [7].
Estrogen replacement therapy in endometrial 
cancer patients
Hormone replacement therapy (HRT) with estrogen with
or without progestins is frequently used to alleviate men-
opausal symptoms but also to reduce the risk of oste-
oporosis and cognitive dysfunctions. In endometrial
carcinomas HRT may be believed to be critical due to fear
of initiating growth of occult residual tumor cells, result-
ing in disease recurrence and shortened survival. As sum-
marized by the American College of Obstetricians and
Gynecologists (ACOG) there is not enough data to draw
any final conclusion. Any decision on the subject should
thus be individualized based on potential benefit and risk
to the patient [132]. Some studies which have addressed
this subject covered only a small number of patients in
regard to the overall excellent prognosis of endometrial
cancer patients. Of all these studies, however, none
produced evidence that patients should not receive estro-
gen [133-136]. On the contrary, some studies reported an
even prolonged survival for patients (with low-risk factors
for recurrence, namely, low tumor grade (grades 1 and 2),
less than 1/2 myometrial invasion, and no metastases to
lymph nodes or other organs,) who received estrogen
[134,136]. Furthermore, the introduction of selective
estrogen receptor modulators (SERM) has also offered
new treatment options which will also have to be studied
in the future.
Comparison of recurrence-free survival between in patients undergoing adjuvant radiotherapy with respect to anemia Figure 7
Comparison of recurrence-free survival between in patients undergoing adjuvant radiotherapy with respect to anemia. Log 
Rank = 9.1; df = 1; p < 0.003.World Journal of Surgical Oncology 2004, 2:24 http://www.wjso.com/content/2/1/24
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Final remarks
Endometrial carcinomas represent a very frequent tumor
entity in industrialized countries. It is hard to believe how
little evidence-based data exists on even the important
aspects of the disease. This may be partially due to the
overall good prognosis even if surgery is reduced to hyster-
ectomy and adnectomy. However, the high incidence in
the developed world and consequently many women suf-
fering relapses, necessitates the research of new
approaches for cancer recurrence. Recent research suggests
that therapy with trastuzumab (Herceptin®) could per-
haps improve the outcome in HER-2/neu overexpressing
tumors [137]. Further research will focus on molecules
and pathways responsible for the initiation and growth of
endometrial carcinomas, including tumor suppressor
genes, DNA mismatch repair genes, oncogenes, molecules
involved in adhesion and invasion and angiogenesis
[138]. This research will hopefully allow the development
of specific and selective inhibitors.
Some advances may also be possible with – conventional
treatment, especially radiotherapy. Recent findings of a
retrospective analysis suggest that tumor oxygenation may
play an important role during adjuvant radiotherapy of
endometrial carcinomas. Patients with normal hemo-
globin levels during therapy (according to the definition
of the EORTC = 12.0 g/dl) have a substantially better over-
all and recurrence free survival (Figure 7) [139]. Due to
this strong impact on patients' health, these aspects
require further studies.
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